{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:50:28Z","timestamp":1778867428559,"version":"3.51.4"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Warfarin patient self-management (PSM) has consistently demonstrated superior efficacy to clinic-based management and is recommended by evidence-based guidelines, but it is virtually unused in the US health care system.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To implement and evaluate warfarin PSM in the US health care system using strategies developed to overcome previously identified barriers associated with PSM underutilization.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a single-group implementation open-label trial conducted between March 2023 and January 2024 at 4 specialized anticoagulation management services facilities in the US. Patients who participated had been taking warfarin for at least 9 months and were using home international normalized ratio monitors. The follow-up period was 6 months. Data were analyzed between July and December 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Transition to warfarin PSM using an implementation toolkit developed to address barriers specific to the US health care system.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Implementation and clinical outcomes were assessed using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework and included the proportion of participants successfully transitioned to PSM, time in the therapeutic international normalized ratio range, bleeding and thromboembolic events, and proportion of international normalized ratios managed independently by participants.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 255 patients invited to participate in the trial, 138 (54.0%) consented (mean [SD] age, 63.2 [13.2] years; 80 male [58.0%]; 117 White [84.8%]; 123 non-Hispanic or Latino [89.1%]); 127 participants (92.0%) had been receiving warfarin therapy for 2 or more years. Among participants, 120 (87.0%) successfully transitioned to PSM and completed 6 months of follow-up. Compared with baseline, time in therapeutic range during PSM improved from 77.1% (95% CI, 73.7%-80.6%) to 81.3% (95% CI, 78.1%-84.4%). During the PSM phase, 5 bleeding events and no thromboembolic events or deaths occurred. Differences in adverse events in the 6 months before and after PSM initiation were not statistically significant. Most (83.0%) warfarin dosing decisions were made independently by participants and rarely required intervention from clinicians due to safety concerns. At the conclusion of the study, 98 participants (84.4%) expressed a preference for continuing PSM and clinicians expressed comfort with 109 participants (94.0%) continuing PSM.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this single-group implementation trial, warfarin PSM was safely and effectively implemented. These results provide critically needed evidence to facilitate and accelerate PSM implementation in the US health care system.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04766216<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.2627","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:30:37Z","timestamp":1773934237000},"page":"e262627","source":"Crossref","is-referenced-by-count":1,"title":["Warfarin Patient Self-Management in the US Health Care System"],"prefix":"10.1001","volume":"9","author":[{"given":"Daniel M.","family":"Witt","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"Health Thrombosis Service, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heeseung","family":"Hong","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"Health Thrombosis Service, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Wilson","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey E.","family":"Jones","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"Health Thrombosis Service, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara R.","family":"Vazquez","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"Health Thrombosis Service, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer J.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"Health Thrombosis Service, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"},{"name":"IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan B.","family":"King","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Utah, Salt Lake City"},{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn W.","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh","family":"Chan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Loma Linda Healthcare System, Loma Linda, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Delate","sequence":"additional","affiliation":[{"name":"Kaiser Permanente National Pharmacy, Aurora, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"2","key":"zoi260112r1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"70","author":"Nishimura","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zoi260112r2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation.","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260112r3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults.","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi260112r4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cardfail.2024.07.024","article-title":"Antithrombotic strategies with left ventricular assist devices.","volume":"30","author":"Cikes","year":"2024","journal-title":"J Card Fail"},{"issue":"2_Suppl","key":"zoi260112r5","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy.","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"10","key":"zoi260112r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry.","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"issue":"13","key":"zoi260112r7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.113.002601","article-title":"National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation.","volume":"129","author":"Dlott","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"zoi260112r8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dsx.2017.09.005","article-title":"A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus.","volume":"12","author":"Olczuk","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"zoi260112r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102712","article-title":"Comparative effectiveness of warfarin management strategies: a systematic review and network meta-analysis.","volume":"74","author":"Dhippayom","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi260112r10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003839.pub3","article-title":"Self-monitoring and self-management of oral anticoagulation.","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"zoi260112r11","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"36","key":"zoi260112r12","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease.","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"zoi260112r13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy.","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"3","key":"zoi260112r14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jac5.1912","article-title":"A qualitative study exploring patient experiences and opinions of warfarin patient self-management in the US healthcare system.","volume":"7","author":"Wilson","year":"2024","journal-title":"J Am Coll Clin Pharm"},{"issue":"12","key":"zoi260112r15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/jac5.1879","article-title":"A qualitative study evaluating provider perceptions of implementing warfarin patient self-management in the United States healthcare system.","volume":"6","author":"Wilson","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"issue":"1","key":"zoi260112r17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback.","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement Sci"},{"issue":"3-4","key":"zoi260112r18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10464-012-9522-x","article-title":"The quality implementation framework: a synthesis of critical steps in the implementation process.","volume":"50","author":"Meyers","year":"2012","journal-title":"Am J Community Psychol"},{"issue":"3","key":"zoi260112r20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","article-title":"Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.","volume":"50","author":"Curran","year":"2012","journal-title":"Med Care"},{"key":"zoi260112r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"zoi260112r22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi260112r23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","article-title":"RE-AIM Planning and Evaluation Framework: adapting to new science and practice with a 20-year review.","volume":"7","author":"Glasgow","year":"2019","journal-title":"Front Public Health"},{"issue":"6","key":"zoi260112r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158071","article-title":"Development and validation of an oral anticoagulation knowledge tool (AKT).","volume":"11","author":"Obamiro","year":"2016","journal-title":"PLoS One"},{"key":"zoi260112r25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1477-7525-10-120","article-title":"The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients.","volume":"10","author":"Cano","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"zoi260112r26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-Item Health Survey 1.0.","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ"},{"issue":"3","key":"zoi260112r27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy.","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"11","key":"zoi260112r28","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"zoi260112r29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"zoi260112r30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2018.01.024","article-title":"Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service.","volume":"163","author":"Phelps","year":"2018","journal-title":"Thromb Res"},{"issue":"5","key":"zoi260112r31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"issue":"19","key":"zoi260112r32","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","article-title":"Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.","volume":"126","author":"Van Spall","year":"2012","journal-title":"Circulation"},{"key":"zoi260112r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tru.2022.100105","article-title":"Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management.","volume":"7","author":"Saunders","year":"2022","journal-title":"Thromb Update"},{"key":"zoi260112r34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11606-023-08348-4","article-title":"Outcomes of warfarin home INR monitoring vs office-based monitoring: a retrospective claims-based analysis.","volume":"39","author":"Van Beek","year":"2023","journal-title":"J Gen Intern Med"},{"key":"zoi260112r16","doi-asserted-by":"crossref","unstructured":"Hong? H, Wilson? AS, Jones? AE, . Overcoming barriers to warfarin patient self-management (PSM) in the US healthcare system: implementation trial study protocol.? medRxive. Preprint published online August 21, 2025. doi:10.1101\/2025.08.18.25333912","DOI":"10.1101\/2025.08.18.25333912"},{"key":"zoi260112r19","unstructured":"Johnson? K, Gustafson? D, Ewigman? B, . Using rapid-cycle research to reach goals: awareness, assessment, adaptation, acceleration. Agency for Healthcare Research and Quality report No 15-0036. June 2015. Accessed January 6, 2023. https:\/\/williamgmcgowanfund.org\/wp-content\/uploads\/2020\/11\/EvalMeth01-AHRQ-Rapid-Cycle-Research-Guide.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846713\/witt_2026_oi_260112_1773348756.6862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:30:39Z","timestamp":1773934239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846713"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.2627","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}